The Norwegian Investment Company Saga Pure ASA has entered into an agreement to invest NOK 75 mill into Sarsia Seed portfolio company Heimdall Power AS to help accelerate the company's growth strategy.  The total transaction was 155mNOK involving existing investors...

Sarsia Seed portfolio company Coegin Pharma AB was yesterday listed on Nordic SME stock exchange.  (Ticker: COEGIN) Read more

Sarsia Seed portfolio company Vaccibody AS - was today listed on Oslo Stock Exchange´s Merkur Markets list.                                                                                                                                                                 ...

It was announced today that Sarsia Seed portfolio company Vaccibody AS enters into $715m lisence and collaboration agreement with Genentech.Low double-digit tiered royalties on sales of commercialized products arising from the partnership are in addition.             ...

Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR)  announce that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's...

Vaccibody announces First Patient Dosed in its VB C-02 trial; a multi-centre, open-label Phase II clinical trial testing a combination of Vaccibody’s VB10.16, a targeted DNA vaccine, and Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in...

US biopharmaceutical company Rallybio has announced that they have completed a USD 145 mill Series B financing to advance the company's portfolio of product candidates targeting devastating rare diseases. Rallybio's lead candidate is RLYB211 that the company acquired...

BerGenBio today announced that the company has raised mNOK via a private placement that took place via an accelerated book building process after close of market on 4 May 2020.  Read more

BerGenBio announces that bemcentinib has been selected to be fast-tracked in a new UK national multi-centre randomised Phase 2 clinicial trial initiative that aims to get an early indication of whether bemcentinib could save lives and improve outcomes in the most...

Vaccibody AS announces that it will register on the Norwegian OTC-list (“NOTC”), owned and operated by Oslo Børs, from  January 27. Vaccibody will trade under the ticker “VACC”. Read more